Test directory: Keppra (Levetiracetam)

Ordering Code 7990
Test Name Keppra (Levetiracetam)
Alias Levetiracetam
Keppra
Preferred Specimen Serum
Preferred Container Plain (Red)
Optimum Volume 1 mL
Collection Instructions A steady state, trough (pre-dose) sample is generally accepted as most consistent for therapeutic drug monitoring of Levetiracetam

Brivaracetam (Briviact) interferes with this assay.
Handling Instructions Centrifuge and separate within 2 hours of collection.
Transport Requirements Oahu: Refrigerated
Airline: Refrigerated
Specimen Stability Ambient: Not Stable
Refrigerated: 1 Week
Frozen: 4 Weeks
Rejection Criteria Gel barrier tube, SST specimens unacceptable
Avail. Stat NO
Analytic Time 1-2 Days
Methodology Quantitative Enzyme Immunoassay
Reference Lab  Clinical Laboratories of Hi

Reference range(s)

The reference ranges listed below are valid on this date of May 31, 2025.
Component Age Male Norm Male Critical Low Male Critical High Female Norm Female Critical High Female Critical Low Units Add'l info
Keppra Level ALL 12.0-46.0 12.0-46.0 mcg/mL

The reference...
The reference range for levetiracetam has not been well established. Therapeutic benefit may be achieved with serum drug concentrations outside of these ranges and toxicity may occur at levels below the reference range. The reference range reflects trough serum concentrations drawn just prior to the next dosage

Brivaracetam (Briviact) interferes with measurements of levetiracetam (Keppra) using this assay. Patients undergoing a switch in drug therapy involving Keppra and Briviact should not be monitored for levetiracetam using this assay
Serum levels of levetiracetam and/or brivaracetam should be confirmed by a valid chromatographic method if there is a possibility these drugs are co-present in circulation
Note1

Note1:


The reference range for levetiracetam has not been well established. Therapeutic benefit may be achieved with serum drug concentrations outside of these ranges and toxicity may occur at levels below the reference range. The reference range reflects trough serum concentrations drawn just prior to the next dosage

Brivaracetam (Briviact) interferes with measurements of levetiracetam (Keppra) using this assay. Patients undergoing a switch in drug therapy involving Keppra and Briviact should not be monitored for levetiracetam using this assay
Serum levels of levetiracetam and/or brivaracetam should be confirmed by a valid chromatographic method if there is a possibility these drugs are co-present in circulation
.